CoChat

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Open access
Machado, Marina Amaral de Ávila, de Moura, Cristiano Soares, Chan, Kelvin, Curtis, Jeffrey R., Hudson, Marie, Abrahamowicz, Michal, Jamal, Rahima, Pilote, Louise, Bernatsky, Sasha · 2020 · Scientific Reports

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation in an unselected population-based cohort of adults with metastatic melanoma who started therapy with pembrolizumab, nivolumab, or nivolumab/ipilimumab from January 2015 to August 2017. Therapy discontinuation was defined as a gap between doses beyond 120 days, and/or initiation of another cancer therapy. We estimated drug-specific rate ratios for therapy discontinuation adjusted for age, sex, comorbidities, health care use, and past cancer therapies. We included 876 metastatic melanoma patients initiating pembrolizumab (44.3%), nivolumab/ipilimumab (31.2%), and nivolumab (24.5%). At 12 months of follow-up, the probabilities of therapy discontinuation were 49.9% (95% confidence interval, CI 43.6–56.5) for pembrolizumab, 58.8% (95% CI 50.5–67.3) for nivolumab, and 59.2% (95% CI 51.7–66.8) for nivolumab/ipilimumab. Stratified analyses based on prior cancer therapy, brain metastases at baseline, and sex showed similar trends. In multivariable analyses, compared with pembrolizumab, patients starting nivolumab (rate ratio 1.38, 95% CI 1.08–1.77) or nivolumab/ipilimumab (rate ratio 1.30, 95% CI 1.02–1.65) were more likely to discontinue therapy. Our findings indicate frequent discontinuations of checkpoint inhibitors at one year. The lower discontinuation associated with pembrolizumab should be confirmed in further studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-71788-z

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of cohort selection. *Time zero: date of the first claim of pembrolizumab, nivolumab, or nivolumab/ipilimumab.
Figure 1 Flow diagram of cohort selection. *Time zero: date of the first claim of pembrolizumab, nivolumab, or nivolumab/ipilimumab.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 14

Metadata

Authors
Machado, M. A. D. Á., de Moura, C. S., Chan, K., Curtis, J. R., Hudson, M., Abrahamowicz, M., Jamal, R., Pilote, L., & Bernatsky, S.
Affiliations
  • McGill University (CA)
  • Sunnybrook Health Science Centre (CA)
  • University of Alabama at Birmingham (US)
  • Jewish General Hospital (CA)
  • Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author
Bernatsky, Sasha
Venue
Scientific Reports
Published
2020-09-03
Volume
10
Issue
1
Pages
14607-14607
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3082399821
Cited by
14
References
24
Citations by year
2026: 4 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 1
FWCI
0.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
metastatic melanoma, immune checkpoint inhibitors, treatment discontinuation, pembrolizumab, nivolumab, real-world evidence, immunotherapy, brain metastases, sex differences
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Immune Checkpoint Inhibitors, Aged, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Withholding Treatment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. https://app.cochat.ai/papers/10.1038/s41598-020-71788-z
The paper
Machado, M. A. D. Á., de Moura, C. S., Chan, K., Curtis, J. R., Hudson, M., Abrahamowicz, M., Jamal, R., Pilote, L., & Bernatsky, S. (2020). Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. Scientific Reports. https://doi.org/10.1038/s41598-020-71788-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.